HARBIN, China, May 21 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company in the People's Republic of China ("PRC"), today announced that it signed an agreement with Taiwan Golden Biotechnology Corporation to begin cooperating on the development of a new anti-cancer drug called Antroquinonol.
Golden Biotechnology Corporation specializes in the development of new bio-medicines based on its research in the fields of modern biotechnology and molecular medicine. Antroquinonol is a kind of compound extracted from Antrodia Cinnamomea Chang & Chou, a rare medicinal fungus that grows naturally inside the Cinnamonum kanehirae tree trunk, a native tree species of Taiwan. It can be used in the treatment of liver cancer and lung cancer.
The so called "King of Medical Fungi" and "Ruby of Taiwan's Forest,"
Antrodia Cinnamomea Chang & Chou has been widely used by the Taiwanese since
it can eliminate toxins, protect the liver, improve the immune system, fight
allergies, and reduce blood fat. Golden Biotechnology Corporation's research
department accidentally discovered Antroquinonol when it was studying the
efficacy of the extract from Antrodia Cinnamomea Chang & Chou. In further
study, Antroquinonol has been proven to restrain the growth and reproduction
of cancer cells, thought the existing extracts take effect slowly due to low
concentration of Antroquinonol. Through sophisticated extraction techniques,
Golden Biotechnology Corporation acquired pure Antroquinonol, which has been
granted patents in 60 countries. Pre-clinical research on Antroquinonol has
been completed in the United Kingdom and in the United States the compound has
been approved by the U.S. FDA to enter into first stage clinical tri
|SOURCE China Sky One Medical, Inc.|
Copyright©2009 PR Newswire.
All rights reserved